Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

In today’s world, losing weight isn’t just about fitting into your old jeans—it’s about reclaiming your energy, confidence, ...

A recent study suggests that liraglutide, a drug similar to Ozempic, may reduce migraine frequency in obese individuals with ...

The Semaglutide market is projected to expand from US$ 27.15 billion in 2024 to US$ 61.7 billion by 2033, with a CAGR of 9.55% from 2025. Driven by r ...

Already a household name in diabetes and weight management, Ozempic (semaglutide) may soon find another surprising role — as ...

Oh My Meds LogoOh My Meds expands nationwide with personalized peptide therapies, offering virtual care and fast home ...

I was just a baby scientist when I discovered the hormone that made Ozempic possible. I had no idea how life-changing—and ...

Mounjaro offers up to 20% weight loss – but it’s not for everyone. Learn about eligibility, alternatives and why long-term habits still matter most.